Specificity requirement for FDC and concomitant medication [Bioanalytics]

posted by qualityassurance – 2023-07-07 11:06 (86 d 05:51 ago) – Posting: # 23659
Views: 487

Hi Karthik,

My opinion is that your validation should mimic the actual study condition. In BE studies of FDC, plasma samples contains all the analytes of interest and hence CC/QC during validation should contain the other analyte at ULOQ concentration or cmax concentration.

What is opinion of other (bioanalytical) experts?


Complete thread:

UA Flag
 Admin contact
22,763 posts in 4,775 threads, 1,628 registered users;
17 visitors (0 registered, 17 guests [including 3 identified bots]).
Forum time: 16:58 CEST (Europe/Vienna)

Restlessness is discontent –
and discontent is the first necessity of progress.
Show me a thoroughly satisfied man 
and I will show you a failure.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz